Patent Assignment
Reel/Frame 075830/0409
Assignment of Assignor's Interest
Recorded: 2026-08-28
Pages: 18
Assignor
DEKA BIOSCIENCES, INC.
Executed: 2026-05-27
Assignee
DEKA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
3945 FREEDOM CIRCLE, SUITE 560, SANTA CLARA, CALIFORNIA, 95054
Covered Properties
(31)
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Dual Cytokine Fusion Proteins Comprising Il-10
Application:
18/909,739 →
Publication:
US US20250135241A1
Antibody Variable Domain Regions Fused to Il-10 Variant Molecules
Methods for Treating Malignant Tumors with Il-10 Variant Conjugates
Il-10 Variant Molecules and Methods of Treating Inflammatory Disease
Antibody-Il-10 Fusion Proteins
Il-10 Variant Molecules Conjugated with Antibody Variable Domain Regions
Il-10 Variant Molecules and Methods for Treating Inflammatory Disease and Oncology
Application:
18/657,437 →
Publication:
US US20240294591A1
Il-10 Variant Molecules and Methods for Treating Inflammatory Disease and Oncology
Application:
19/390,302 →
Publication:
US US20260125435A1
Method of Using Genetic Markers, Single Nucleotide Polymorphisms and/or Indels to Determine Responsiveness to Il-10 or Il-10 Derivative Treatment
Application:
17/145,169 →
Publication:
US US20210214782A1
Dual Cytokine Fusion Proteins Comprising Multi-Subunit Cytokines
Application:
19/271,002 →
Publication:
US US20260132179A1
Use of Dual Cytokine Fusion Proteins Comprising Il-10 and Adoptive Cell Therapies or Bispecific T-Cell Engagers to Treat Cancer
Application:
18/067,535 →
Publication:
US US20230210953A1
Method of Reducing Bispecific T Cell Engager or Chimeric Antigen Receptor T Cell Mediated Cytokine Release Syndrome Using Interleukins-4, -10, or a Fusion Protein Thereof
Method of Reducing Bispecific T Cell Engager or Chimeric Antigen Receptor T Cell Mediated Cytokine Release Syndrome Using Interleukins-4, -10, or a Fusion Protein Thereof
Application:
19/452,149 →
Publication:
US US20260226123A1
Related Assignments
(4)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Aug 4, 2021
From: MUMM, JOHN
To: DEKA BIOSCIENCES, INC.
Reel/Frame 057078/0429 →
Assignment of Assignor's Interest
Jul 5, 2022
From: MUMM, JOHN
To: DEKA BIOSCIENCES, INC.
Reel/Frame 060397/0070 →
Assignment of Assignor's Interest
Nov 6, 2023
From: MUMM, JOHN
To: DEKA BIOSCIENCES, INC.
Reel/Frame 065472/0893 →
Assignment of Assignor's Interest
Aug 28, 2026
From: DEKA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: IOVANCE BIOTHERAPEUTICS, INC.
Reel/Frame 075830/0464 →